Viewing Study NCT00216632


Ignite Creation Date: 2025-12-24 @ 9:55 PM
Ignite Modification Date: 2025-12-25 @ 7:34 PM
Study NCT ID: NCT00216632
Status: COMPLETED
Last Update Posted: 2012-12-07
First Post: 2005-09-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
Sponsor: Janssen Pharmaceutica N.V., Belgium
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module